Abstract: Protein microspheres are produced by contacting an aqueous solution of a macromolecule and a polymer with a surface at a high surface area to volume ratio, and heating the solution. The microspheres are useful for preparing pharmaceuticals of defined dimensions which can be delivered to a patient by inhalation therapy.

Abstract: A coating for an implantable medical device is disclosed, the coating including a self-assembled molecular structure. The coating can be used for altering the release rate of a therapeutic substance from the implantable device.

Abstract: The present invention relates to a series of novel silicone polyesters which are prepared by crosslinking a dimethicone copolyol having at least 4 hydroxyl groups with a dimer acid. The ratio of acid groups to hydroxyl groups ranges from 0.7 to 1.4 so that a significant number of groups are reacted and a significant number of crosslink groups are achieved.

Abstract: Cosmetic compositions in the form of soft solids having in combination an improved resistance to syneresis and retained efficacy and which contain a particulate antiperspirant suspended in a water-immiscible carrier liquid structured by a structurant system are obtainable by employing as carrier liquid a mixture of a hydrocarbon oil and an aromatic ester oil in a weight ratio of from 1:2 to 15:1 and as structurant system from 5.5 to 20% in total of a di or triblock alkylene/arylene block copolymer and an organic wax in a weight ratio to each other of from 5:1 to 30:1.

Abstract: Carboxylic-gated-nitroxide (CGN) compounds and their esterified derivatives are discovered and disclosed as compositions and shown to have the potential in treating a variety of acute and chronic diseases and disorders resulting from reactive oxygen species (ROS) injury. Compositions for treating tissue damage from ROS injury containing CGN, or active derivatives thereof, in a suitable pharmaceutical, cosmetic, and diagnostic formulations are described.

Abstract: A method and nutrient supplement composition for nocturnal administration to human subjects where the nutrient supplement composition includes both a sustained timed release portion and a rapid release portion, both portions containing a mixture of edible food proteins and edible amino acid building blocks with a portion of these key components being microencapsulated for sustained timed release in a the human body during the growth hormone spikes that generally occur during nocturnal sleep.

Abstract: Biocompatible polymers and adhesives have a cyanoacrylic core and other substituents such as therapeutic agents, targeting moieties, imaging agents, amino acid residues or other organic moieties. Exemplary uses of inventive compositions include use as sealants and adhesives for medical uses, and as polymeric formulations for biocompatible implants and matrices and drug delivery.

Abstract: Random three- and four-amino acid copolymers having lengths of 14-, 35- and 50-amino acid residues are provided. Fifty-mers of FEAK were effective inhibitors of MBP 85-99 or proteolipid protein (PLP) 40–60-specific HLA-DR-2-restricted T cell clones. These copolymers efficiently suppressed EAE induced in susceptible SJL/J (H-2s) strain of mice with either whole spinal cord homogenate (WSCH) or with the encephalitogenic epitope PLP 139-151. YFAK 50-mer having a molar ratio of about y 0.8:F 0.2 inhibited binding of biotinylated MBP 85-99 epitope to HLA-DR-2 molecules more efficiently than either unlabeled MBP 85-99 or Copaxone®. YFAK and FAK copolymers efficiently suppressed EAE induced in SJL/J (H-2s) mice with the encephalitogenic epitope PLP 139-151.

Abstract: Carboxylic-gated-nitroxide (CGN) compounds and their esterified derivatives are discovered and disclosed as compositions and shown to have the potential in treating a variety of acute and chronic diseases and disorders resulting from reactive oxygen species (ROS) injury. Compositions for treating tissue damage from ROS injury containing CGN, or active derivatives thereof, in a suitable pharmaceutical, cosmetic, and diagnostic formulations are described.

Abstract: A wet granulation process in which a pharmaceutical substance is granulated using a granulating fluid which is a halogenated hydrocarbon which has a normal boiling point below ambient temperature, for example 1,1,1,2-tetraflouroethane, under a pressure sufficient to maintain the halogenated hydrocarbon in a liquid state. A process in which the halogenated hydrocarbon is re-cycled, and suitable equipment for performing the process is also described.